HOME > TOP STORIES

TOP STORIES

ORGANIZATION Mr Sawai of JGA Announces “Absolute Opposition” to Add’l Price Reduction for Generics

December 20, 2011
REGULATORY MHLW Subcommittee Agrees on Mandatory Notification of Package Inserts

December 19, 2011
REGULATORY Expert Subcommittee Agrees to 2-Year Continuation of Trial of Premium for New Drug Development

December 19, 2011
BUSINESS ReproCELL to Commercialize World’s 1st iPS Cell-Derived Hepatocytes in April

December 16, 2011
REGULATORY Public-Private Dialogue to Set Next Strategic Plan for Innovative Drug Discovery

December 15, 2011
ORGANIZATION Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development

December 15, 2011
REGULATORY CSIMC Approves Draft Measures to Promote Generic Drug Use

December 15, 2011
BUSINESS MTPC to Focus on Development of Global Human Resources

December 14, 2011
ORGANIZATION Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report

December 14, 2011
BUSINESS Wholesalers Eager to Begin Category-Based Price Negotiations After FY2012 Price Revision

December 13, 2011
REGULATORY MOF Asks MHLW for Add’l 10% Price Cut for Long-listed Drugs

December 12, 2011
REGULATORY 11 APIs/26 Products to Return Premium for New Drug Development

December 9, 2011
REGULATORY Payers, Care Providers Agree at CSIMC on Need for Price Cuts for Long-listed Drugs

December 8, 2011
BUSINESS Towa Pharmaceutical to Expand Dealings with Regional Foundation Hospitals

December 7, 2011
BUSINESS Growth for All Products Is Indispensable: President Alvarez of MSD

December 7, 2011
BUSINESS Sandoz Aiming for Top-10 Position in Japan within 3-5 Years

December 7, 2011
BUSINESS Toray to Accelerate Pharmaceutical Business, Targeting ¥40 Billion in Sales

December 6, 2011
REGULATORY MHLW Reform Plan Calls for “Reductions in NHI Prices of Original Drugs”

December 6, 2011
REGULATORY NHI Price Revision Rate of 6% Expected for FY2012; Higher If Long-listed Drugs Receive Add’l Price Cut

December 5, 2011
REGULATORY Average Discrepancy Rate Remains at Approximately 8.4%: MHLW Flash Report

December 2, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Japan’s Biological Raw Material Rules Enter Major Revision; Clarity on Benefits and Safety Holds Key

By Sakura Kono

Japan is poised to make the most sweeping revision in eight years to the Standards for Biological Raw Materials —…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…